Best Resource Development Cell Podcasts (2024)

1
A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino 28:06

24h ago28:06

28:06

We love to hear from our listeners. Send us a message. Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene e…

1
Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts 25:13

15d ago25:13

25:13

We love to hear from our listeners. Send us a message. Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL rema…

1
CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D. 27:58

29d ago27:58

27:58

We love to hear from our listeners. Send us a message. Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program for Drug Development: Guidance for Industry. She also…

1
Identifying Drug Development Opportunities for DMD with CureDuchenne 29:55

2M ago29:55

29:55

We love to hear from our listeners. Send us a message. Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene …

1
Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington 21:01

2M ago21:01

21:01

We love to hear from our listeners. Send us a message. Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. They discuss…

1
TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D. 35:30

3M ago35:30

35:30

We love to hear from our listeners. Send us a message. KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the S…

1
Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft 27:52

3M ago27:52

27:52

We love to hear from our listeners. Send us a message. Strand Therapeutics' CEO and Co-Founder Jake Becraft joins Erin Harris to discuss genetic regulation and how the company's programmable mRNA constructs combine genes for self-replication derived from RNA viruses with genetically programmed logic circuits that control the location, timing, and i…

1
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko 14:52

4M ago14:52

14:52

We love to hear from our listeners. Send us a message. Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.…

1
The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley 25:21

4M ago25:21

25:21

We love to hear from our listeners. Send us a message. Dr. Bambi Grilley is Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine AND she is Chief Regulatory Officer at ISCT. Dr. Grilley talks to us about her role as CRO at ISCT and th…

1
Dr. Bruce Levine on ISCT and the Future of CAR-T 31:49

4M ago31:49

31:49

We love to hear from our listeners. Send us a message. In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for solid tumors, autoimmune disease, and more. He talks about his time and learnings as President…

1
CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant 18:51

5M ago18:51

18:51

We love to hear from our listeners. Send us a message. Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech American Gene Technologies (AGT). He spent his career on the front lines of HIV treatment and research and remains an advocate for the HIV patient. He formed…

1
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah 29:39

5M ago29:39

29:39

We love to hear from our listeners. Send us a message. BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripote…

1
Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang 23:08

5M ago23:08

23:08

We love to hear from our listeners. Send us a message. In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how Vor has treated 8 patients demonstrating clinical proo…

1
Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan 19:37

6M ago19:37

19:37

We love to hear from our listeners. Send us a message. Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-prec…

1
Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D. 17:17

6M ago17:17

17:17

We love to hear from our listeners. Send us a message. On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Life Biosciences' CSO, Sharon Rosenzweig-Lipson, Ph.D., about the Boston-based biotech's cellular rejuvenation therapies for the treatment of age-related diseases. They cover Life Biosciences' lead program, a gene therapy ca…

1
The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz 27:31

7M ago27:31

27:31

We love to hear from our listeners. Send us a message. Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Laboratory’s (JAX) Rare Disease Translational Center (RDTC)'s VP, Cat Lutz. They discuss RDTC's mission, the specific qualifications that make up a rare di…

1
Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald 20:48

7M ago20:48

20:48

We love to hear from our listeners. Send us a message. On this episode of Cell & Gene: The Podcast, Christopher McDonald, Global Head of Technical Operations at Kite, a Gilead company, talks to Host Erin Harris about Kite's recent FDA approval of manufacturing process change resulting in reduced median turnaround time for Yescarta. They talk throug…

1
Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng. 37:17

8M ago37:17

37:17

We love to hear from our listeners. Send us a message. The Dedham Group's Jennifer Klarer, M.Sc.Eng., Partner and Head of Cell & Gene Therapy, joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value for CGTs. Klarer shares a detailed breakdown of the most misunderstood aspects of cell and gene therapy pr…

1
Breaking Down Solid Tumors with Triumvira Immunologics' Dr. Paul Lammers 21:33

8M ago21:33

21:33

We love to hear from our listeners. Send us a message. Paul Lammers, M.D., M.Sc., CEO of Triumvira Immunologics joins Cell & Gene: The Podcast to talk to Host Erin Harris about TAC, the company's proprietary T cell Antigen Coupler, which has both autologous and allogeneic approaches. They also discuss targeting relapsed or refractory HER2-positive …

1
4 Keys to Allo in 2024 with Poseida Therapeutics' Kristin Yarema, Ph.D. 31:59

9M ago31:59

31:59

We love to hear from our listeners. Send us a message. Kristin Yarema, Ph.D., CEO, Poseida Therapeutics sits down with Cell & Gene: The Podcast Host Erin Harris to discuss four of the biggest challenges the CGT sector faces when it comes to the development of off-the-shelf therapies. Kristin shares how 2024 might see some real progress in allogenei…

1
Cell Therapy For Corneal Endothelial Dystrophies With Aurion Biotech's Greg Kunst 13:41

9M ago13:41

13:41

We love to hear from our listeners. Send us a message. For this third and final episode recorded at ARM's 2023 Meeting on the Mesa, Cell & Gene: The Podcast Host, Erin Harris, sat down with Greg Kunst, president, CEO, and Board member at Aurion Biotech. Listen in as they discuss the cell therapy used to treat corneal endothelial disease and how Gre…

1
Overcoming the Limitations of CAR T-Cell Therapy with Vittoria Bio's Nick Siciliano, Ph.D. 17:23

10M ago17:23

17:23

We love to hear from our listeners. Send us a message. Vittoria Biotherapeutics’ CEO, Nick Siciliano, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss the company's mission to expand the applications for CAR-based therapeutics by employing novel cell engineering and gene editing technologies.…

1
Gene Therapy Deals, Collaborations, & Partnerships with Astellas' Richard Wilson 25:02

10M ago25:02

25:02

We love to hear from our listeners. Send us a message. Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation at Astellas sat down with Cell & Gene: The Podcast's Erin Harris at ARM's 2023 Meeting on the Mesa to discuss the gene therapy deal making landscape as well as Astellas' recent deals and collaborations. They also disc…

1
The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills 28:34

11M ago28:34

28:34

We love to hear from our listeners. Send us a message. Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene ther…

1
Inside 2023 Meeting on the Mesa with ARM's COO, Rita Johnson-Greene 16:33

11M ago16:33

16:33

We love to hear from our listeners. Send us a message. Alliance for Regenerative Medicine's COO, Rita Johnson-Greene, joined Cell & Gene: The Podcast host, Erin Harris, in person at the 2023 Meeting on the Mesa to discuss this year's event. Johnson-Greene also shared what's ahead for 2024 as the event heads to a new location. They discussed major t…

1
The Future of Cell and Organ Transplantation in Treating T1D with Dr. Camillo Ricordi 18:15

12M ago18:15

18:15

We love to hear from our listeners. Send us a message. A pioneer and an icon in diabetes research, Camillo Ricordi, M.D., is the Professor of Surgery, Director of Cell Transplant Center and Director Emeritus of the Diabetes Research Institute at the University of Miami Miller School of Medicine, Florida (UM-DRI). He joins Cell & Gene: The Podcast's…

1
In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg 30:37

12M ago30:37

30:37

We love to hear from our listeners. Send us a message. Umoja Biopharma's CEO, Andy Scharenberg, M.D., joins Cell & Gene: The Podcast's Erin Harris to discuss the evolution of allogeneic, in vivo CAR-T cell therapeutics. They discuss The Climb, or The Colorado Laboratory and Innovation Manufacturing Building, which is Umoja’s lentiviral vector devel…

1
Inside Genome Editing with CBER's Dr. Peter Marks 25:17

1y ago25:17

25:17

We love to hear from our listeners. Send us a message. The FDA's Center for Biologics Evaluation and Research (CBER)'s Dr. Peter Marks makes his second appearance on Cell & Gene: The Podcast. This time Dr. Marks talks to Host, Erin Harris, about base editing and prime editing and their potential to meet unmet medical need. They discuss what clinica…

1
The Future of CAR-T with Bristol Myers Squibb's Lynelle Hoch 25:53

1y ago25:53

25:53

We love to hear from our listeners. Send us a message. As SVP Cell Therapy Franchise Lead at Bristol Myers Squibb, Lynelle Hoch leads her team to bring more curative cell-based therapies to patients. She joins Cell & Gene: The Podcast's Host, Erin Harris, to discuss the near-term future of CAR-T. They also take a deep dive into the various innovati…

1
The Promise of Genome Editing with Caribou Biosciences' Rachel Haurwitz, Ph.D. 23:21

1y ago23:21

23:21

We love to hear from our listeners. Send us a message. On this episode of Cell & Gene: The Podcast, Rachel Haurwitz, Ph.D., CEO at Caribou Biosciences joins Host Erin Harris to discuss the evolution of genome editing, its present state, as well as its undeniable potential. They also discuss Caribou's chRDNA genome editing technology and how it diff…

1
Focus Areas For Cell Therapy With Bristol Myers Squibb's Stephan Krause, Ph.D. 19:29

1y ago19:29

19:29

We love to hear from our listeners. Send us a message. In June 2023, PDA held its Advanced Therapy Medicinal Products Conference in Baltimore, MD. At the conference, Stephan Krause, Ph.D., Executive Director, AS&T, CT Global Quality at Bristol Myers Squibb, sat down with Cell & Gene: The Podcast Host Erin Harris to discuss the event's major themes …

1
The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault 29:17

1y ago29:17

29:17

We love to hear from our listeners. Send us a message. Dr. Francois Vigneault, Co-Founder, President, and CEO at Shape Therapeutics joins Cell & Gene: The Podcast's Erin Harris to discuss how RNA technologies are shaping the future of gene therapy. They also discuss AI's role in gene therapy as well as the how the CGT sector is benefiting from RNA,…

1
Inside Prime Editing with Prime Medicine's Dr. Andrew Anzalone 24:34

1y ago24:34

24:34

We love to hear from our listeners. Send us a message. Dr. Andrew Anzalone, Head of the Prime Editing Platform and Scientific Co-Founder of Prime Medicine joins Cell & Gene: The Podcast to talk with Host Erin Harris about prime editing - what it is and why it is a major technological advancement in gene editing. Anzalone explains why prime editing …

1
Navigating CMC Challenges with Parenteral Drug Association's Glenn Wright 24:55

1+ y ago24:55

24:55

We love to hear from our listeners. Send us a message. Glenn Wright, President and CEO of Parenteral Drug Association (PDA), sat down with Cell & Gene: The Podcast's Erin Harris at the 2023 PDA ATMP conference to discuss not only the conference's theme, “Navigating Through CMC Challenges,” but also Wright's take on CGT manufacturing strategy based …

1
An Interview with Dr. Usman "Oz" Azam 27:37

1+ y ago27:37

27:37

We love to hear from our listeners. Send us a message. Dr. Usman "Oz" Azam is CEO of Inspirna now but has spent much of his career in the cell and gene therapy space dedicating years as Novartis’ Global Head of Cell & Gene Therapy, President and CEO of Tmunity Therapeutics, and more. Given Oz’s tenure in cell and gene therapy space, I invited him t…

1
Targeting Oncogenic Drivers for Solid Tumor Cancers with Affini-T Therapeutics' Dr. Jak Knowles 23:45

1+ y ago23:45

23:45

We love to hear from our listeners. Send us a message. Affini-T Therapeutics combines a validated TCR discovery platform with synthetic biology switches to attack tumor biology at its root cause. Co-Founder, CEO, and President Dr. Jak Knowles joins Cell & Gene: The Podcast Host Erin Harris to discuss how the company engineers immune cells to target…

1
TJU's Jefferson Institute for Bioprocessing's Impact on CGT with Parviz Shamlou 42:20

1+ y ago42:20

42:20

We love to hear from our listeners. Send us a message. Parviz Shamlou, Vice President and Executive Director at Thomas Jefferson University joins Cell & Gene: The Podcast to talk to Host Erin Harris about Jefferson Institute for Bioprocessing (JIB), the full-service development and training organization specializing in biopharmaceuticals and biolog…

1
Computational Biology's Role In Gene Therapy With Kriya Therapeutics' Dr. Shankar Ramaswamy 31:57

1+ y ago31:57

31:57

We love to hear from our listeners. Send us a message. Shankar Ramaswamy, M.D., CEO & Co-Founder, Kriya Therapeutics joins Cell & Gene: The Podcast's Erin Harris for a discussion on the evolving role computational biology plays in gene therapy development. They also discuss the company's lessons learned from building its own North Carolina-based in…

1
The Near-Term Future of Exosome Science with Capricor Therapeutics' Dr. Linda Marbán 28:17

1+ y ago28:17

28:17

We love to hear from our listeners. Send us a message. Dr. Linda Marbán, Ph.D., CEO of Capricor Therapeutics, a clinical-stage biotech focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases, joins Cell & Gene: The Podcast's Erin Harris to discuss the current state and the near-term fut…

1
Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon 40:51

1+ y ago40:51

40:51

We love to hear from our listeners. Send us a message. In December 2022, Atara Biotherapeutics’ Ebvallo received European Commission approval as the first-ever therapy for adults and children with EBV+ PTLD. The ground-breaking approval represents the first approval of an allogeneic T-cell immunotherapy ever, globally. Atara Bio's CEO, Pascal Touch…

1
The Potential of RNA Exon Editing with Ascidian Therapeutics' Romesh Subramanian, Ph.D. 20:40

1+ y ago20:40

20:40

We love to hear from our listeners. Send us a message. Cell & Gene: The Podcast Host, Erin Harris, welcomes Romesh Subramanian, Ph.D., CEO of Ascidian Therapeutics, a Boston-based biotech focused on rewriting RNA to the pod. During the episode, Subramanian defines RNA exon editing, and they discuss the differences between RNA exon editing and gene …

1
Automating Processes to Scale CGT Manufacturing with PA Consulting's Paolo Siciliano 31:52

1+ y ago31:52

31:52

We love to hear from our listeners. Send us a message. When it comes to manufacturing, many cell and gene therapy companies struggle to automate the diverse processes needed to scale manufacturing. London-based PA Consulting's Associate Partner, Paolo Siciliano, talks to Cell & Gene: The Podcast's Erin Harris about how lean, small biotechs with lim…

1
The Why Behind In-House Manufacturing With Sangamo's Andy Ramelmeier 21:42

1+ y ago21:42

21:42

We love to hear from our listeners. Send us a message. On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Andy Ramelmeir, EVP Head of Technical Operations at Sangamo Therapeutics, a biotech based in Brisbane, California that applies cell and gene therapy to combat Hemophilia A and other genetic diseases. Ramelmeir explains the w…

1
2023 Market Outlook with AdBio and ISCT's Miguel Forte 26:34

1+ y ago26:34

26:34

We love to hear from our listeners. Send us a message. Miguel Forte is Entrepreneur in Residence at AdBio, a VC firm based in France, and President Elect of ISCT. Forte and Cell & Gene: The Podcast host, Erin Harris, break down market outlook perspective for the cell and gene therapy space. He provides valuable tips to employ when seeking VC partne…

1
CMC and Scale Up with Mustang Bio's Robert Sexton 36:05

1+ y ago36:05

36:05

We love to hear from our listeners. Send us a message. MustangBio's Robert Sexton, VP Program and Alliance Leadership, explains the why behind the need for this role in any CGT company. Having worked for Novartis, Sanofi, Legend Biotech, and more, with responsibilities having included quality, operations, and order management, Sexton is currently r…

1
Mindful Parenting: What it is and Why it's Important 10:30

1+ y ago10:30

10:30

Ye Rang Park, a research assistant professor at FRC, discusses in a new FRC podcast a study she conducted on mindful parenting as well as her new community-based participatory project through cross-discipline collaboration. Parents who are interested in how mindful parenting can reduce conflicts with their children and promote positive youth behavi…

1
An Interview with Dr. Peter Marks 28:34

1+ y ago28:34

28:34

We love to hear from our listeners. Send us a message. Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) within the Food and Drug Administration (FDA) sits down with Cell & Gene: The Podcast host Erin Harris to discuss the most anticipated areas of innovation in clinical development, and he offers recommendations …

1
Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth 26:58

2y ago26:58

26:58

We love to hear from our listeners. Send us a message. Shoreline Biosciences' Chief Scientific Officer Dr. Robert Hollingsworth shares his insight on intelligently designed allogeneic off-the-shelf, standardized, and targeted iPSC-derived natural killers (NK) and macrophage cellular immunotherapies. He explains the company's preclinical testing on …

1
The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg 28:35

2y ago28:35

28:35

We love to hear from our listeners. Send us a message. BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as…

1
Manufacturing at the Point of Care with Orgenesis' CEO Vered Caplan 36:45

2y ago36:45

36:45

We love to hear from our listeners. Send us a message. Orgenesis' CEO, Vered Caplan explains the business model behind providing cell and gene therapies that may be manufactured at the point of care. She details how working with hospitals and healthcare providers to enable them to participate in CGT development on their sites and providing these th…

Podcasts Worth a Listen

Resource Development Cell Podcasts

Podcasts Worth a Listen

Quick Reference Guide